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ABSTRACT
Neuroblastoma, the most common extracranial solid tumor in childhood, remains a therapeutic
challenge. However, one promising patient treatment strategy is the delivery of anti-tumor ther-
apeutic agents via mesenchymal stromal cell (MSC) therapy. MSCs have been safely used to
treat genetic bone diseases such as osteogenesis imperfecta, cardiovascular diseases, autoim-
mune diseases, and cancer. The pro-inflammatory cytokine interferon-gamma (IFNc) has been
shown to decrease tumor proliferation by altering the tumor microenvironment (TME). Despite
this, clinical trials of systemic IFNc therapy have failed due to the high blood concentration
required and associated systemic toxicities. Here, we developed an intra-adrenal model of neu-
roblastoma, characterized by liver and lung metastases. We then engineered MSCs to deliver
IFNc directly to the TME. In vitro, these MSCs polarized murine macrophages to the M1 pheno-
type. In vivo, we attained a therapeutically active TME concentration of IFNc without increased
systemic concentration or toxicity. The TME-specific IFNc reduced tumor growth rate and
increased survival in two models of T cell deficient athymic nude mice. Absence of this benefit
in NOD SCID gamma (NSG) immunodeficient mouse model indicates a mechanism dependent
on the innate immune system. IL-17 and IL-23p19, both uniquely M1 polarization markers, tran-
siently increased in the tumor interstitial fluid. Finally, the MSC vehicle did not promote tumor
growth. These findings reveal that MSCs can deliver effective cytokine therapy directly to the
tumor while avoiding systemic toxicity. This method transiently induces inflammatory M1 mac-
rophage polarization, which reduces tumor burden in our novel neuroblastoma murine model.
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SIGNIFICANCE STATEMENT
Despite the rapidly expanding field of immune therapy, major advances in the treatment of
solid tumors have not been realized. This is due in part to the protective tumor microenviron-
ment, which fashions an immune suppressive milieu that hinders immune responses. This arti-
cle demonstrates proof-of-concept that directly introducing interferon-g secreting mesenchymal
stromal cells (MSCs) into an orthotopic neuroblastoma xenograft can induce transient macro-
phage repolarization and a pro-inflammatory environment without systemic cytokine exposure.
While MSC-delivered interferon-g showed anti-tumor activity alone, further tangible benefits
may lie in potentiating existing and future therapies to develop effective solid tumor cellular
immune therapy.
INTRODUCTION
Neuroblastoma is the most common extracranial
solid tumor in childhood and arises from the
developing nervous system’s sympathetic ganglia
[1]. Tumors commonly occur in the adrenal gland
or in the paraspinal sympathetic chain; specific
genetic mutations of the tumor, age at diagnosis,
and local invasiveness/metastasis are used to
stratify patients into risk groups for treatment.
The most common genetic mutation in neuro-
blastoma occurs in the MYCN gene, with gene
amplification (>10 copies) being one of the
most important prognostic indicators. The stan-
dard of care consisting of surgical resection, che-
motherapy, and radiotherapy has not changed
for decades. While many low-risk patients will
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achieve long-term survival, high-risk patients will frequently
relapse with aggressive, therapy-resistant tumors [2]. Currently
we lack established, effective therapies for these patients. Thus,
those that do not respond to the primary therapy are left in the
unacceptable position of having a dismal prognosis without stan-
dard treatment options.
The only optimistic exception to this state is the develop-
ment of dinutuximab, a monoclonal antibody directed at GD2
expression on neuroblastoma cells, which fosters immune-
mediated tumor elimination [3]. Dinutuximab’s FDA approval
in 2015 signified acceptance of the idea that immune therapy
can be used to treat neuroblastoma. However, the insufficient
response to new cellular therapies (e.g., chimeric antigen
receptor-expressing T cells) reminds us that the immune-
suppressive tumor microenvironment (TME) remains a major
obstacle to increasing the long-term survival of children with
neuroblastoma.
Effectively killing cancer cells is complicated by multiple fac-
tors within the TME [4]. For example, cancer cells secrete a
dense matrix which physically impedes the body’s immune cells
or drugs from accessing the cancer cells. Moreover, drug and
immune cell penetration is impaired by convoluted, disorga-
nized vasculature. Nonetheless, immune cells such as tumor
infiltrating lymphocytes (TILs) and tumor-associated macro-
phages (TAMs) do find their way into the tumor but are either
ineffective due to the immune suppressive microenvironment
(e.g., TILs) or worse, contribute to immune suppression them-
selves (e.g., TAMs). This latter mechanism is particularly impor-
tant because immunity should be the body’s best defense
against cancer. By abrogating immune suppression in the TME
and stimulating the immune cells to regain responsiveness, it
may be possible to reactivate immune defense against cancer.
In this work, we use mesenchymal stromal cells (MSCs) as
vehicles to deliver the pro-inflammatory cytokine interferon-
gamma (IFNg). MSCs are found throughout the body but
migrate to specific tissues in the context of remodeling and
regeneration [5]. In some cancers, MSCs can suppress antitu-
mor immune activity in the tumor tissue [6]. However, MSCs
are a valuable treatment tool because they can be readily
modified to robustly secrete immune-modulating molecules
[7, 8]. Our group was the first to infuse allogeneic MSCs into
pediatric patients with osteogenesis imperfecta and the first
to introduce genetically modified MSCs into patients [9].
There are over 950 MSC clinical trials in place, as of January
2018, focusing on all organ systems (https://ClinicalTrials.gov).
Here, we exploit the treatment potential of MSCs by engi-
neering human MSCs to express and secrete IFNg, one of the
most important molecules in suppressing cancer development
and progression [10]. IFNg has been shown to decrease blood
vessel formation in tumors, increase immune cell activation
and the consequent recognition of cancer cells, and decrease
cancer cell proliferation [11]. IFNg has been approved for the
treatment of adult T cell leukemia in Japan, but clinical trials
in the United States, while promising, have yet to yield an
FDA-approved cancer treatment [12]. Despite the positive
effects of IFNg on cancer cells, systemic administration is
associated with significant adverse side effects, including nau-
sea, depression, fever, and leukopenia [13]. By directly intro-
ducing IFNg into the tumor, we propose to eliminate systemic
toxicities while preserving the anti-cancer benefits. Here, we
demonstrate that direct injection of IFNg-expressing MSCs
into the tumor activates the innate immune system, resulting
in decreased tumor growth and increased overall survival.
MATERIALS AND METHODS
Lentivirus Generation and Transfection
Lentiviruses were generated in HEK293T/17 cells using pHIV-
enhanced green fluorescent protein (EGFP), a gift from Bryan
Welm & Zena Werb (Addgene 21373, Cambridge, USA),
psPAX2, a gift from Didier Trono (Addgene plasmid # 12260),
and pMD2.G, a gift from Didier Trono (Addgene plasmid #
12259). Human IFNc (gene ID 3458) and murine IFNc (gene ID
15978) were cloned into the plasmid at the BamHI insertion
site. Lentiviral titers were determined as described in [14].
MSCs
MSCs were isolated and expanded as previously described
[15]. The marrow was taken from the residua (waste) of bone
marrow harvest collection bags obtained from healthy donors
undergoing marrow harvest for clinical indications. The proto-
col was classified as exempt from oversight by the Institu-
tional Review Board of Nationwide Children’s Hospital. At
passage 3, we confirmed that these MSCs met the criteria
proposed by International Society for Cellular Therapy [16].
Cell Culture
CHLA-255 cells expressing luciferase (CHLA-255-luc) and CHLA-
20 neuroblastoma cell lines were generously provided by Dr.
Shahab Asgharzadeh at the Children’s Hospital of Los Angeles.
CHLA-255-luc and CHLA-20 cells were grown in IMDM modified
media (Iscove’s Modified Dulbecco’s Medium) (GE Healthcare,
Chicago, USA) supplemented with 1% antibiotic solution (Corn-
ing, New York, USA) and 20% fetal bovine serum (FBS) (Gemini
Bio-Products, Sacramento, USA). Primary murine macrophages
were cultured in Dulbecco’s modified Eagle’s medium (Corning
Cellgro) supplemented with 1% antibiotic/antimycotic solution
and 10% FBS and 30% L929-cell conditioned medium as a
source of granulocyte/macrophage colony stimulating factor
[17]. Recombinant murine IFNg (mIFNg) was obtained from
PeproTech (Rocky Hill, USA). Cell proliferation was measured
using colorimetric MTS assay (BioVision, San Francisco, USA).
Primary Murine Macrophages
Femurs and tibias were obtained from 6–12 week-old C57BL/6
mice. After removal of both epiphyses, a syringe was used to
flush phosphate buffered saline (PBS) through the bone marrow
cavity to exude bone marrow. Bone marrow homogenates were
treated with ammonium-Chloride-Potassium (ACK) lysing buffer
to remove red blood cells and placed into culture. Cells were
seeded in non-tissue culture treated Petri dishes and cultured
for 7 days prior to stimulation. The resulting macrophages were
then treated with mIL-4 (30 ng/ml), mIFNg (50 ng/ml), or co-
cultured with equivalent number of MSCs for 4 days.
Mice
NOD SCID gamma mice (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
were obtained from The Jackson Laboratories (Bar Harbor,
USA). Colonies of this strain were established and maintained
in the vivarium in The Research Institute at Nationwide Child-
ren’s Hospital. Athymic nu/nu (nude) mice were obtained
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from Envigo (Huntingdon, UK). Clinical and anatomic pathol-
ogy was performed as described in [18]. All animal protocols
were approved by the Institutional Animal Care and Use Com-
mittees of the Research Institute at Nationwide Children’s
Hospital.
Establishment of Orthotopic Tumor Model
Female nude mice, aged 6–8 weeks, and female NSG mice,
aged 2–4 months, were anesthetized with an i.p. injection of
ketamine (100 mg/kg) and xylazine (10 mg/kg). A transverse
incision approximately 8 mm in length was made over the left
flank just posterior to the spleen and ribcage. Following the
opening of skin and underlying muscle, 3.75 3 106 neuroblas-
toma cells in 100 ml 25% Matrigel (Corning) PBS solution
were injected under the adrenal capsule toward the superior
pole of the kidney. Muscle and skin were then closed with a
4-0 polysorb suture.
Ultrasound-guidance injection was used to deliver MSCs
directly to the tumor when the tumor reached 0.5–1 volume
equivalents of the kidney. Injections were done under general
anesthesia using isoflurane. Tumor development was moni-
tored via ultrasound (VisualSonics Vevo 770) and biolumines-
cence. Mice were injected with 30 mg/ml D-luciferin
(Biosynth Chemistry and Biology, Staad, Switzerland) 20
minutes prior to imaging using Xenogen IVIS Spectrum. Mice
were euthanized upon meeting the following endpoint crite-
ria: any tumor diameter 1 cm or any animal that demon-
strated >20% weight loss. Mice were euthanized by terminal
cardiac bleed under isoflurane followed by cervical dislocation
and vital organ removal. This timing is subsequently denoted
“endpoint.”
Macrophage Depletion In Vivo
Mice were treated with 200 ml liposomal clodronate or con-
trol liposomes (Clodrosome, Brentwood, USA) i.p. 2 days prior
to tumor implantation. After tumor implantation, all mice
received 100 ml i.p. three times weekly for the duration of
the experiment.
Flow Cytometry
All flow cytometry was performed using BD LSR II. Whole
tumors were homogenized in PBS solution containing 150 mg/
ml DNase 1 (Sigma-Aldrich, St. Louis, USA) and 25 mg/ml liber-
ase blendzyme (Sigma-Aldrich). Tumors were then strained
through a 70 mm filter and red blood cells were lysed using
ACK lysing buffer (ThermoFisher, Waltham, USA). Tumor cell
suspensions were then washed with PBS and stained using
the following antibodies: CD45 (BioLegend 103126, San Diego,
USA), CD11b (BD Pharmingen 557397, San Jose, USA), F4/80
(BioLegend 123116), and CD90 (Biolegend 328122).
Gene Profiling
RNA was harvested from cells using RNeasy mini kit (Qiagen).
cDNA was generated using high-capacity cDNA reverse tran-
scription kit (ThermoFisher). qPCR analysis (quantitative poly-
merase chain reaction) was performed using Taqman gene
expression assays and Applied Biosystems StepOne Plus
thermocycler.
Cytokine Profiling
Tumor interstitial fluid (TIF) was collected as described by
Haslene-Hox et al. [19]. Briefly, tumors were halved, placed
over a 40 mm strainer, and centrifuged at 106g for 10
minutes. Blood was collected from mice by terminal cardiac
bleed and whole mouse blood was allowed to clot at room
temperature for 30 minutes. Serum was isolated from the
clots by centrifugation at 1,500g for 10 minutes. Cytokine
concentration was determined using Bio-Plex kits (Bio-Rad
M60009RDPD, 171GA005M, 171V4001M) and Bio-Plex sus-
pension array system.
IFNc Release and Activity
MSC-mIFNg cells were cultured for 1–3 days, followed by super-
natant collection. Supernatants were clarified by centrifugation
at 400g for 5 minutes. mIFNg concentration was determined by
ELISA (R&D DY485, Minneapolis, USA). IFNg activity was deter-
mined by cytopathic effect (CPE)-based anti-viral assay (AVA)
testing, performed by UCyTech (Utrecht, Netherlands).
Immunofluorescence Staining
Mice were euthanized according to approved protocol and tis-
sue samples were excised. Lungs were partially infused with
10% formalin to expand tissue. Tissue samples were fixed in
10% buffered formalin and embedded in paraffin. Five micro-
meter sections were mounted to slides. Slides were immersed
in 100 nM sodium citrate buffer and placed in decloaking
chamber (BioCare Medical, California, USA) for 25 minutes.
The following reagents were used: normal donkey serum
(Jackson Immunoresearch 017-000-121, West Grove, USA),
monoclonal rabbit anti-human CD90 antibody (1:200, Clone
EPR3132; Abcam, Cambridge, USA), biotinylated anti-GFP
(1:200, Novus Biologicals NB100–1678, St. Louis, USA), DAPI
(Life Technologies D3571, Carlsbad, USA), anti-goat Alexa 488
(Invitrogen A11055, Waltham, USA), anti-rabbit Alexa 555
(Invitrogen A31572), ProLong Gold antifade reagent (Invitro-
gen P36930). Images were taken using Zeiss Axio Imager.A1
and AxioCam MRm Rev.3 at 3200 magnification.
Statistical Analysis
Statistical analyses were performed by unpaired two-tailed t
test for comparison of two samples, and by one-way analysis
of variance for multiple samples followed by Tukey’s multiple
comparisons test, using Prism (Version 6; GraphPad Software,
Inc., San Diego, USA). Survival curves were compared using
the log-rank Mantel-Cox test. Outliers were identified and
removed by extreme studentized deviate method. All data are
shown as mean6 SE. A p value <.05 was considered statisti-
cally significant. In all figures, statistical significance is indi-
cated as follows: (*) denotes p< .05, (**) denotes p .01,
(***) denotes p .001, (****) denotes p .0001, and (n.s.)
or no symbol represents no significant difference.
RESULTS
Intra-Adrenal Neuroblastoma Xenograft Model
In an effort to study the clinically relevant role of the TME in neu-
roblastoma, we developed an intra-adrenal xenograft model of
human neuroblastoma. We chose to use nude mice, which lack
Relation, Yi, Guess et al. 3
www.StemCells.com VC AlphaMed Press 2018
functional T cells, in order to explore the role of the innate
immune system in the absence of T cell immunity. CHLA-255 cell
line, derived from human neuroblastoma metastatic site, was
chosen due to its reported high CCL2 expression levels and sensi-
tivity to macrophage polarization [20]. After CHLA-255-luc cells
were injected under the adrenal capsule (Fig. 1A), tumors could
be first visualized via ultrasound at 10–14 days as indicated by an
opaque structure anterior to the kidney (identified by visible renal
pyramids) (Fig. 1B). Tumors became palpable through the skin
near endpoint, and calipers were used to determine endpoint for
mice based on a tumor diameter 1 cm.
Gross analysis of the tumors revealed minimal invasion
into the ipsilateral kidney. Ipsilateral adrenal glands were
spared by the tumor, and contralateral kidneys demonstrated
no gross abnormalities (Fig. 1C). Histological analyses of the
tumors were consistent with neuroblastoma, with dense
hypercellularity [21] (Fig. 1D). Metastases were identified in
lungs and liver (Fig. 1E, 1F), consistent with sites of metastasis
found clinically [2, 22].
Generation of mIFNc-Expressing MSCs
Human MSCs were transduced with a bicistronic lentiviral vec-
tor that expresses mIFNg and EGFP under the control of the
viral long terminal repeat (LTR). Transduction efficiency at day
3 was 89.7%6 0.8%, n5 3 (Fig. 2A). Transduced MSCs
secreted 69.16 14.3 pg mIFNg/106 MSCs/24 hours (Fig. 2B)
and exhibited no difference in proliferation over 5 days (Sup-
porting Information Fig. S1). To confirm the biologic activity of
mIFNg secreted from human MSCs, we compared our
secreted cytokine with commercially available recombinant
mIFNg. MSC-secreted mIFNg showed 1.26 0.25 3 107 units/
mg protein which was statistically similar to the activity of
recombinant mIFNg (4.96 0.1 3 106 units/mg protein)
assayed in parallel (Fig. 2C). IFNg activity was determined by
CPE-based AVA testing, performed by UCyTech.
MSC-mIFNc Induces M1 Macrophage Polarization In Vitro
We next examined the ability of mIFNg-secreting MSCs (MSC-
mIFNg) to polarize primary murine macrophages in vitro.
Figure 1. Intra-adrenal capsule murine model of neuroblastoma. CHLA-255-luc or CHLA-20 human neuroblastoma cells suspended in
25% Matrigel (arrowhead) were injected into the adrenal capsule caudal to the adrenal gland (solid arrow) (A). Tumors were identifiable
via ultrasound between 10 and 14 days post-injection (p.i.). Clockwise from top left: no tumor, 11, 15, 31 days p.i. Tumors are circled by
white dotted line (B). Tumors spared ipsilateral kidney and adrenal gland (white arrow) on gross histology (C). Representative H&E stain-
ing of tumor (D), lung metastases (E), and liver metastases (F).
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Primary bone marrow-derived macrophages (BMDM) were
treated with 50 ng/ml recombinant mIFNg (M1) or 30 ng/ml
recombinant mIL-4 (M2) for 4 days. Following cell harvest
and cDNA synthesis, samples were probed for expression of
M1 polarization markers IL-6, NOS2, CCL2, and CD38 [23–25]
and M2 polarization markers Arg1, IL-10, and Mrc1/CD206
[26, 27]. Compared to untreated cells, BMDM exposed to
mIFNg demonstrated significantly increased expression of
M1 markers while BMDM exposed to mIL-4 demonstrated
significantly increased expression of M2 markers (Fig. 2D).
This process was then repeated using BMDM co-cultured
with MSC-mIFNg and control MSCs. Co-culture of BMDM
with MSC-mIFNg similarly significantly increased expression
of these M1 markers and decreased expression of M2
markers (Fig. 2E). Fold changes for each gene are listed in
Table 1.
Supernatants from co-culture samples were analyzed for
cytokine expression. Co-culture with MSC-mIFNg increased
expression of inflammatory M1-related cytokines IL-1a, IL-1b,
IL-6, G-CSF, TNFa, and RANTES/CCL5, but no significant change
in IL-12p40 (Fig. 2F). These findings indicate that MSC-mIFNg
polarize macrophages to the inflammatory M1 phenotype in
vitro. Despite reports that unmodified MSCs can polarize mac-
rophages toward the M2 alternative activation phenotype [28,
29], our findings suggest that the presence of MSCs does not
impede the polarizing effect of mIFNg.
MSC-mIFNc Slows Tumor Growth and Increases
Overall Survival
Next, we examined the effect of MSC-mIFNg delivered
directly into the TME. Because IFNg does not cross-react
between mouse and human, mIFNg introduced into the
tumor will stimulate murine cells only, including the immune
system, but will not directly affect the human tumor nor have
an autocrine effect on the human MSCs. Ultrasound tumor
monitoring revealed the average time for the tumors to reach
Figure 2. MSC-mIFNg polarize M1 macrophages in vitro. Bicistronic lentiviral vector that expresses murine interferon-gamma (mIFNg)
and EGFP reaches peak infectivity 3 days post-infection in human MSCs (p5 .0455) (A). MSC-mIFNg release 69.16 14.3 pg mIFNg/106
MSCs/24 hours (p5 .0024) (B). Activity of lentivirally-produced mIFNg was not statistically different when compared to recombinant
mIFNg (C). Bone marrow-derived macrophages (BMDM) cultured with 30 ng/ml recombinant mIL-4 demonstrated increased mRNA
expression of M2 activation markers Arg1, IL-10, and Mrc1 (D). BMDM cultured with recombinant mIFNg 50 ng/ml (D) and BMDM co-
cultured with MSC-mIFNg (E) demonstrated increased mRNA expression of M1 activation markers IL-6, NOS2, and CD38, while CCL2 was
upregulated in recombinant mIFNg treated BMDM only. Co-culture of MSC-mIFNg with BMDM increases cytokine expression of IL-1a
(p5 .0023), IL-1b (p5 .0231), IL-6 (p< .0001), G-CSF (p5 .0064), TNFa (p5 .0012), and RANTES (p5 0.0308). IL-12p40 was not signifi-
cantly upregulated (F). Statistical significance is indicated as follows: (*) denotes p< .05, (**) denotes p .01, (***) denotes p .001,
(****) denotes p .0001, and (n.s.) or no symbol represents no significant difference. Abbreviations: EGFP, enhanced green fluorescent
protein; mIFNg, murine interferon-gamma; MSC, mesenchymal stromal cell; N.D., not detected.
Table 1. Gene expression changes in primary bone marrow-
derived macrophages in vitro
Gene
mIFNg vs. control mIL-4 vs. control MSC-mIFNg vs. MSC
Fold change p value Fold change p value Fold change p value
IL-6 12.36 4.7 .0001 2.56 0.2 .0578 28.66 0.7 <.0001
NOS2 2.96 0.2 .0001 0.36 0 .0001 38.56 0.5 <.0001
CCL2 3.26 0.9 .0001 0.26 0 .0001 0.56 0 .3800
CD38 1.46 0.4 .0174 0.76 0.1 .0519 5.66 0.1 <.0001
Arg1 2.36 0.4 .9956 3,342.96 21.4 .0001 0.76 0.1 .1332
IL-10 1.66 0.8 .0069 7.36 0.3 .0001 0.26 0 .0003
Mrc1 0.26 0 .0004 7.16 0.2 .0001 0.16 0 <.0001
BMDM were cultured in mIFNg or mIL-4, and gene expression
changes were compared to untreated BMDM. BMDM were co-
cultured with MSC-mIFNg, and gene expression changes were com-
pared to co-culture with MSC.
Abbreviations: BMDM, bone marrow-derived macrophages; mIFNg,
murine interferon-gamma; MSC, mesenchymal stromal cell.
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0.5–1 kidney volume equivalents was 21 days after tumor
placement. At that time, tumors were directly injected with
graded doses of MSC-mIFNg or PBS. While a dose of 3 3 104
MSC-mIFNg showed no benefit, doses of 1 3 105 and 3 3
105 MSC-mIFNg significantly increased overall survival by
33% (Fig. 3A). Since the two higher doses did not produce
statistically different survival outcomes, we chose to proceed
with the minimal effective dose (MED) of 1 3 105 MSC-
mIFNg. Mice treated with MSC-mIFNg were analyzed at end-
point by postmortem examination to identify occult organ
toxicity or tumor formation. The complete blood counts and
white blood cell subset proportions were within the expected
range for nude mice. Similarly, serum chemistries in the 1 3
105 MSC-mIFNg treatment group were within the normal
range for all mice (data not shown). Metastases were identi-
fied in the lungs and liver in all groups, as expected in this
neuroblastoma model. We did not identify any additional
metastases, non-neuroblastoma occult malignancies, or organ
toxicity.
To confirm that this survival benefit is not unique to the
CHLA-255-luc tumor model, we next examined MSC-mIFNg
treatment in CHLA-20 human neuroblastoma cell line, derived
from primary tumor. This model was chosen because, like
CHLA-255, the cell line secretes the macrophage-attracting
chemokine CCL2 [20, 30], forming tumors with a relatively
abundant population of macrophages. Tumors in this model
reached treatment size at 14 days post-implant. In this model,
MSC-mIFNg treatment produced increased survival by 25%
compared to controls, similar to the former neuroblastoma
model (Fig. 3B).
Because any treatment benefit is constrained by MSC per-
sistence within the tumor, we analyzed MSC content in
tumors by flow cytometry. CHLA-255-luc tumors were har-
vested at 7 days post MSC-mIFNg injection and at endpoint.
While tumors at endpoint did not reveal a measurable popu-
lation of MSC-mIFNg, GFP1 human-CD901 MSCs could be
identified in tumors harvested 7 days post-injection (Fig. 3C).
Because intravenously injected MSCs may accumulate in the
lungs before being cleared through the circulation [31], we
next evaluated the lungs of MSC-mIFNg treated mice. Com-
pared to control mice injected with MSC i.v. 2 hours prior to
tissue harvest (Fig. 3D), tumor-bearing mice showed no identi-
fiable GFP1 human-CD901 MSCs in the lungs (Fig. 3E). These
data indicate limited persistence of MSC-mIFNg within the
tumor after a single dose, which may underlie the limited
duration of tumor growth suppression.
MSC Delivery Vehicle Does Not Impede IFNc-Induced
Tumor Suppression
The role of MSCs in immune activation remains controver-
sial. MSCs have been characterized as pro-inflammatory in
many studies, but other studies reveal an immune-
suppressive role for these cells [32]. This debate reveals the
importance of studying MSCs in their unique microenviron-
ment and the pro- or anti-inflammatory signals they may
receive in situ. Therefore, we next investigated the role of
control MSCs in tumor development. While MSC-mIFNg sup-
presses tumor growth and increases overall survival, an
equivalent number of control MSCs did not produce any sig-
nificant effect (pro- or anti-tumor) when compared to PBS
treated mice (Fig. 4A). Moreover, mice that received 1 3
105 MSC-mIFNg, the MED, or a mixture of 1 3 105 MSC-
mIFNg/9 3 105 control MSC in a single injection demon-
strated a statistically similar outcome (Fig. 4B). These data
Figure 3. MSC-mIFNg increases survival in intra-adrenal neuroblastoma. CHLA-255-luc tumor-bearing mice were treated with either
PBS (n5 9), 3 3 104 (n5 5), 1 3 105 (n5 10), or 3 3 105 MSC-mIFNg (n5 5). 1 3 105 MSC-mIFNg p5 .0048, 3 3 105 MSC-mIFNg
p5 .0135 (A). The minimal effective dose was repeated in CHLA-20 tumor bearing mice (p5 .0066) (B). GFP1 CD901 MSC-mIFNg were
identified by flow cytometry in the tumor at 7 days p.i., but were undetectable at endpoint (p5 .0007) (C). Mice were injected with
MSC-mIFNg intravenously 2 hours prior to lung tissue harvest (D), and lungs from tumor-bearing mice were collected at endpoint (E).
Immunofluorescence staining for GFP and human-CD90 revealed MSCs present in the lungs of mice injected with i.v. MSC-mIFNg but
absent in experimentally treated mice at endpoint (representative images shown, 3200 magnification). Abbreviations: GFP, green fluo-
rescent protein; mIFNg, murine interferon-gamma; MSC, mesenchymal stromal cell; PBS, phosphate buffered saline; p.i., post-injection.
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demonstrate that a ninefold excess of unmodified MSCs
does not hinder the IFNg-induced suppression of tumor
growth nor the consequent survival.
To identify a direct effect of IFNg on the tumor cells and/
or MSCs (both human origin), we generated a lentiviral vector
expressing human IFNg (hIFNg) using the same vector back-
bone. Similar to the mIFNg vector, MSCs reached peak
expression at 3 days post-infection (Fig. 4C). MSC-hIFNg dem-
onstrated a delayed growth rate when compared to MSC and
MSC-mIFNg, indicating a species-specific response to IFNg
(Supporting Information Fig. S1). Mice treated with tumor
injections of MSC-hIFNg did not show a survival difference
compared with controls (Fig. 4D). This finding demonstrates
that IFNg does not have a role in direct tumor cytotoxicity nor
in autocrine stimulation of the MSCs toward an immunosup-
pressive phenotype, thereby promoting tumor proliferation.
Additionally, MSC-secreted IFNg has been reported to stimulate
TRAIL secretion from MSCs in an autocrine fashion [33, 34].
Our data suggest that such a mechanism is not a major compo-
nent in this model, as MSC-hIFNg injection conveyed neither
survival reduction nor benefit.
Role of Macrophages in Tumor
At this juncture, our data suggest MSC-mIFNg therapy sup-
presses tumor proliferation without a direct effect on the
tumor or MSCs. In our nude mouse xenograft, T cells are lack-
ing but B cells and the entire innate immune system are
intact. To begin to elucidate the mechanism of IFNg activity,
we assessed the effect of treating CHLA-255-luc tumors gener-
ated in NSG, which do not have any intact innate or adaptive
immune function. MSC-mIFNg treatment did not promote sur-
vival in these mice, indicating that monocyte/macrophages,
NK cells, or B cells must underlie the survival benefit
observed in our nude mouse model (Fig. 5A).
While neither NK cells nor B cells respond to IFNg, this
cytokine is considered one of the most potent pro-
inflammatory macrophage activators. Hence, we focused on
the role of TAMs, which generally express an immune-
suppressive M2 phenotype [35]. Ablating host macrophages
via liposomal clodronate removed the therapeutic benefit of
MSC-mIFNg, indicating a macrophage-specific mechanism of
effect (Fig. 5B). However, macrophage prevalence within the
non-ablated tumors, as defined by CD451 CD11b1 F4/801
Figure 4. MSCs are not immune suppressive in this model. CHLA-255-luc tumors were treated with PBS (n5 5), 1 3 105 MSC-mIFNg
(n5 5) or 1 3 105 control MSC (n5 5) (A). Control MSCs did not affect survival, while MSC-mIFNg increased overall survival
(p5 .0198). CHLA-255-luc tumors were treated with PBS (n5 5), 1 3 105 MSC-mIFNg (n5 5) or a mixture of 1 3 105 MSC-mIFNg and
9 3 105 control MSC (n5 5) (B). A ninefold excess of control MSCs did not alter survival, while increased overall survival was observed
in MSC-mIFNg (p5 .0466) and MSC mixture groups (p5 .0180). Bicistronic lentiviral vector that expresses hIFNg and EGFP reaches peak
infectivity 3 days post-infection in human MSCs (Day 2 p5 0.0161, Day 3 p5 0.0039) (C). CHLA-255-luc tumors treated with PBS
(n5 6), 3 3 105 MSC-hIFNg (n5 5), 1 3 105 MSC-hIFNg (n5 5), or 3 3 104 MSC-hIFNg (n5 5) demonstrated no significant difference
(D). Abbreviations: EGFP, enhanced green fluorescent protein; hIFNg, human interferon-gamma; mIFNg, murine interferon-gamma; MSC,
mesenchymal stromal cell; PBS, phosphate buffered saline.
Relation, Yi, Guess et al. 7
www.StemCells.com VC AlphaMed Press 2018
cells, did not differ significantly between PBS treated tumors
at endpoint and MSC-mIFNg treated tumors at 7 days post
treatment and at endpoint (Fig. 5C). This observation indicates
that MSC-mIFNg do not increase macrophage infiltration into
the tumor.
At point of sacrifice, whole blood was collected via terminal
cardiac bleed. Serum was isolated and analyzed alongside TIF.
At 7 days post MSC-mIFNg cell injection or at endpoint, TIF
and serum obtained from the animals were assessed in parallel
for cytokine content. We did not detect significant differences
in serum cytokine expression between these three groups, indi-
cating a tumor-localized effect (Fig. 5D). TIF at 7 days post-
MSC-mIFNg treatment showed significantly elevated levels of
two uniquely M1 inflammatory cytokines, IL-17 and IL-23p19
[24–28]. Unique M2 cytokines IL-10 and TGFb1 were
unchanged in the TIF (Fig. 5E). These data support the hypoth-
esis that MSC-mIFNg transiently repolarize a limited subset of
TAMs, possibly those located proximal to the mIFNg-secreting
MSCs. M2 polarized TAMs do not secrete any IL-23p19 or IL-
17; hence, small increases in secretion are easily measurable.
By contrast, the relative abundance of M2 cytokines renders
small reductions undetectable. These data are important
because, in contrast to surface marker expression, cytokine
release is a functional measure of macrophage polarization.
The serum of treated animals did not show an increase of
IFNg, suggesting that the cytokine does not enter the sys-
temic circulation. This is consistent with the lack of systemic
toxicity. Interestingly, however, we did not detect increased
IFNg in the TIF of treated tumors. Given that we detected M1
macrophage derived cytokines, IFNg must have activated the
TAMs. Rapid IFNg receptor binding/uptake or degradation
within the tumor may explain this observation. Nonetheless,
our data collectively indicate that MSC-mIFNg treatment stim-
ulates a transient pro-inflammatory state within the TME,
likely conferring the observed tumor suppression.
DISCUSSION
Neuroblastoma persists as a devastating disease despite
recent advances in cancer therapeutics [36, 37]. In this work,
we used an intra-adrenal xenograft in an effort to most faith-
fully model the role of the TME in the clinical setting [38].
This model recapitulates the metastatic pattern of neuroblas-
toma, with identifiable distant metastases in the lungs and
liver. We demonstrate that MSCs can be engineered to
directly deliver IFNg to the TME without systemic cytokine
exposure, thereby suppressing tumor growth and extending
survival in two murine models.
The TME remains one of the largest challenges to success-
ful cancer therapies. Through physical and chemical barriers
to therapy penetrance, including a dense extracellular matrix,
tortuous vasculature, aberrant metabolism, and immune sup-
pression, tumors are able to evade detection and immune-
Figure 5. MSC-mIFNg transiently repolarize macrophages to M1 phenotype. CHLA-255-luc tumor-bearing NSG mice treated with PBS
(n5 6) or 1 3 105 MSC-mIFNg (n5 6) demonstrated no difference between groups (A). Host macrophages were ablated from CHLA-
255-luc tumor-bearing athymic mice via liposomal clodronate or were treated with control liposomes. Tumors were treated with PBS
(n5 5 control, n5 4 clodronate) or 1 3 105 MSC-mIFNg (n5 4) (B). Only control liposome treatment and MSC-mIFNg increased overall
survival (p5 .0226). MSC-mIFNg treated tumors from athymic mice were collected at 7 days p.i. and at endpoint; PBS-treated tumors
were collected at endpoint only. CD451 CD11b1 F4/801 macrophage infiltration did not differ significantly between groups (C). IL-17,
IL-23p19, TGFb1, and IL-10 cytokine expression did not differ in any group of serum collected (D), while the tumor interstitial fluid of
MSC-mIFNg treated tumors revealed increased expression of IL-17 (p5 .0115) and IL-23p19 (p5 .0010) at 7 days post-injection (E).
Abbreviations: mIFNg, murine interferon-gamma; MSC, mesenchymal stromal cell; NSG, NOD SCID gamma mice; PBS, phosphate buff-
ered saline; p.i., post injection.
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mediated killing [4]. Altering the TME to facilitate drug deliv-
ery and impact represents a major goal in oncology. Here, we
show that MSC-IFNg promotes an inflammatory microenviron-
ment and boosts the tumor-responsiveness of resident macro-
phages. Thus, our data represent a significant proof-of-
concept that we can effectively retrain a patient’s endogenous
immune system to recognize and respond to cancer.
Cell delivery of IFNg has many advantages over traditional
systemic infusion. Most importantly, direct injection into the
tumor bypasses systemic exposure to IFNg and the associated
toxicities. Additionally, the duration of MSC activity represents
a window of continuous IFNg infusion into the TME as
opposed to a single large dose. Finally, multiple studies have
shown that intravenously infused MSCs can directly traffic to
select tumors, denoting the tumor homing potential of MSCs
[39–41]. Therefore, potential applications of this work include
systemic infusion of MSC-IFNg, which then home to the pri-
mary tumor as well as distant metastases in order to alter
the TME at multiple sites. The possibility of a systemically
infused tumor homing therapy represents an intriguing new
frontier in the use of MSCs in cancer treatment.
We made extensive use of athymic nude mice as the xeno-
graft hosts; this experimental design bears great significance for
the interpretation of our data. In the absence of T cells, eradica-
tion of the tumor is not expected. Macrophage activity alone
will, at best, impede tumor growth or temporarily lessen the
volume of a slowly progressive tumor. Thus, our data demon-
strating short-term tumor suppression is clinically significant and
suggests this approach holds promise. Additionally, we can con-
clude that MSCs do not directly promote the tumor and do not
counter the IFNg effect on macrophages in this model.
The next step in development will be to assess the effect
of MSC-IFNg cell therapy in a fully immune competent animal
model. To obtain full advantage from this treatment model,
repolarized macrophages, and possibly dendritic cells, must pre-
sent antigens and activate T cells. These effector T cells would
then secrete IFNg and possibly initiate a cytokine feedback
loop, obviating the need for ongoing MSC-IFNg therapy. More-
over, repolarization of TAMs might enhance the therapeutic
effects of other immune therapies such as chimeric antigen
receptor T (CAR-T) cell therapy. Combining MSC-IFNg with
other approved immunotherapies has the potential to synergis-
tically improve treatment, but determining which combinations
are most effective must be empirically determined.
TIF analysis reveals a macrophage-dependent mechanism
for the observed survival benefit of MSC-IFNg. Increased cyto-
kine expression of IL-23p19 and IL-17 within the TIF can only
be attributed to resident M1 macrophages, as other potential
sources such as T cells are absent in this model. Changes in
M1 cytokines were detectable, but a relatively small change
of M2 cytokines on a substantial background of TAMs was
not statistically detectable. MSC-mIFNg treatment confers an
unambiguous survival benefit in a T cell deficient model, and
cytokine analysis reveals a functional repolarization of TAMs
to the M1 phenotype. Moreover, the absence of significant
survival benefit in NSG mice and macrophage-ablated mice
also supports this macrophage-based mechanism.
The observed survival difference between MSC-IFNg and
MSC vehicle-only groups indicates that IFNg must be pro-
duced by the cells, but the absence of increased IFNg in the
TIF suggests that IFNg is rapidly bound to neighboring cells.
Therefore, the effect on macrophage repolarization may be
limited locoregionally to the most proximal TAMs. This sug-
gests that a more diffuse injection of MSCs throughout the
tumor might increase treatment response, but such a strategy
is not feasible within this murine xenograft tumor model. The
small tumor size at time of treatment, 0.5–1 volume equiva-
lents of the kidney (0.2 cm3) [42], restricts treatment to
one injection site so as not to destroy tumor tissue via multi-
ple needle insertions. This limitation would not be relevant to
the clinical setting as patients can easily receive injections
into multiple regions of the tumor, thereby dispersing the
MSCs throughout. Similarly, tumor size limits the total volume
and number of MSCs that can be delivered in this model.
Future studies will need to evaluate the optimal treatment
volume, cell dose, and injection sites for MSC-IFNg.
A major asset of this treatment strategy is the absence of
increased macrophage infiltration into the tumor. This is an
important observation, although not unexpected as IFNg’s
major effect on macrophages is polarization and classic activa-
tion [43, 44]. Because the effect on TAMs is short-term,
increased macrophage infiltration into the tumor could ulti-
mately result in greater concentration of tumor-supportive
TAMs. This has important implications for clinical translation,
as a rebound effect in tumor growth following MSC clearance
would potentially negate any conferred treatment benefit.
CONCLUSION
Our findings establish a proof-of-concept that IFNg-secreting
MSCs can be injected into a solid tumor, impact tumor pro-
gression, and confer prolonged survival to the host. While our
data implicate repolarization of TAMs, future studies are
required to fully elucidate the mechanism of anti-tumor activ-
ity. Moreover, macrophage directed therapy in T cell compe-
tent host may show remarkably greater activity than in
immune deficient models. Our future efforts will build on this
essential first step in the development of MSC-IFNg as a via-
ble treatment strategy in patients.
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